Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to 13.2%.

  • Amphastar Pharmaceuticals' EBITDA Margin fell 166400.0% to 13.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.73%, marking a year-over-year decrease of 88800.0%. This contributed to the annual value of 28.06% for FY2024, which is 25100.0% down from last year.
  • Amphastar Pharmaceuticals' EBITDA Margin amounted to 13.2% in Q3 2025, which was down 166400.0% from 24.19% recorded in Q2 2025.
  • Amphastar Pharmaceuticals' EBITDA Margin's 5-year high stood at 40.25% during Q3 2023, with a 5-year trough of 10.0% in Q1 2021.
  • Moreover, its 5-year median value for EBITDA Margin was 23.88% (2023), whereas its average is 23.12%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 209200bps in 2023, then tumbled by -166400bps in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' EBITDA Margin (Quarter) stood at 20.06% in 2021, then surged by 40bps to 28.02% in 2022, then grew by 8bps to 30.31% in 2023, then dropped by -20bps to 24.2% in 2024, then crashed by -45bps to 13.2% in 2025.
  • Its last three reported values are 13.2% in Q3 2025, 24.19% for Q2 2025, and 21.87% during Q1 2025.